TEVA Healthcare

Teva Pharmaceutical Industries Limited

$41.91+2.97%

Price as of close on Nov 3, 2026 · Financials updated Sep 30, 2026

Basics

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Country: Israel
Market cap: 48.9B USD
Enterprise value: 62.1B USD
Full-time employees: 31,173

Overall health

Drawback: higher risk than most peers: less short-term liquidity (current ratio 0.88 vs a peer median of 2.59) and more debt relative to equity (2.18× vs a peer median of 0.22×)higher risk: less liquidity (current ratio 0.88 vs peers 2.59) and more debt vs equity (2.18× vs peers 0.22×)
About average: valuation

Ranks #523 of 1,157 healthcare companies (top 46%)

See how it ranks against its peers

Worth knowing

Earnings turned from a loss to a profit. Profit per share this year after a loss last year.
Teva Pharmaceutical Industries made a profit per share in its latest year after a loss the year before.
Operating margin at a 6-year high. 12% in 2025, the best of the last 6 years.
Teva Pharmaceutical Industries kept 12% of revenue as operating profit in 2025, its highest in the 6 years of filings we have.
Profit is backed by cash. Free cash flow is 191% of reported profit.
Teva Pharmaceutical Industries's free cash flow is 191% of its reported profit, so its earnings are turning into cash it can reinvest, pay out or use to reduce debt.

StockQuotient Score

54/ 100

Oct 5 54 → Nov 4 54

Valuation

Is the price right?

55/100

Moderate

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Helped by:

▲ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield1.4%

SEC filings · 12 months to Jun 2026Reported value30% base weight · Z-score -0.02Sector median: 0.0148 · MAD: 0.0148

EBITDA yield6.9%

Yahoo Finance fallback · SEC enterprise value unavailable (debt or EBITDA not reported in standard form) · trailing 12 monthsReported value50% base weight · Z-score 0.71Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield2.8%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingReported value20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield15.9%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

76/100

Moderate

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Stronger than most peers on:

▲ EPS growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

Earnings per share turned from a loss to a profit33% base weight · Z-score 4.46Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth4.9%

SEC filings · 3 years to Jun 2026Reported value33% base weight · Z-score -0.12Sector median: 0.0584 · MAD: 0.0840

Revenue growth4.1%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -0.20Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

80/100

Strong

3/3 inputs reported · High confidence

Since last quarter: ▼ Weaker

Operating margin fell 3.9 points to 9.3%

Why

Stronger than most peers on:

▲ ROIC

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin9.3%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 0.18Sector median: 0.0706 · MAD: 0.1217

Return on assets1.8%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 0.02Sector median: 0.0166 · MAD: 0.0537

Return on invested capital30.9%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 2.61Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin52.5%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity9.1%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Higher

Higher relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ Current ratio
▼ Debt / equity

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta0.80

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -0.50Sector median: 0.6250 · MAD: 0.3380

Current ratio0.88×

SEC filings · latest balance sheetReported value33% base weight · Z-score -1.23Sector median: 2.5860 · MAD: 1.3850

Debt / equity2.18×

Yahoo Finance fallback · no standard SEC debt tagReported value33% base weight · Z-score -9.59Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Teva Pharmaceutical Industries

Is Teva Pharmaceutical Industries getting weaker?: Its latest SEC filing (Jul 29, 2026) got weaker in some ways: operating margin fell 3.9 points to 9.3%. Its overall score is unchanged at 54/100 since Oct 28, 2026.
How is Teva Pharmaceutical Industries valued vs its peers?: Priced about in line with its peers. Valuation scores 55/100 against 1,393 healthcare peers. EBITDA yield 6.9% vs a peer median of 4.0% (stronger than 68% of peers).EBITDA yield 6.9% vs peers 4.0% (stronger than 68% of peers).
Is Teva Pharmaceutical Industries growing?: Yes, faster than most of its peers. Growth scores 76/100 against 1,393 healthcare peers.
How profitable is Teva Pharmaceutical Industries?: More profitable than most of its peers. Profitability scores 80/100 against 1,393 healthcare peers. Return on invested capital 30.9% vs a peer median of 4.7% (stronger than 93% of peers).Return on invested capital 30.9% vs peers 4.7% (stronger than 93% of peers).
How risky is Teva Pharmaceutical Industries?: Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 0.88× vs a peer median of 2.59× (weaker than 93% of peers).Current ratio 0.88× vs peers 2.59× (weaker than 93% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Jul 29, 2026 · compared with the quarter ended Mar 31, 2026

Got weaker

Operating margin fell 3.9 points to 9.3%

	Previous quarter	Latest quarter	Change
Revenue (12 months)	17.3B USD	17.3B USD	−0.2%
Net income (12 months)	1.6B USD	706.0M USD	−54.9%
Operating margin	13.2%	9.3%	−3.9 pts
Free cash flow (12 months)	1.2B USD	1.3B USD	+14.9%
Cash	3.7B USD	3.7B USD	−2.3%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Gross margin	47.8%	46.7%	48.2%	48.7%	51.8%	▲ 3.0 pts
Operating margin	10.8%	-14.7%	2.7%	-1.8%	12.5%	▲ 14 pts
Net margin	2.6%	-16.4%	-3.5%	-9.9%	8.2%	▲ 18 pts
Return on assets (ROA)	0.9%	-5.6%	-1.3%	-4.2%	3.5%	▲ 7.6 pts
Return on equity (ROE)	4.1%	-31.3%	-7.4%	-30.5%	17.8%	▲ 48 pts
Free cash flow margin	1.5%	7.0%	5.3%	4.5%	6.7%	▲ 2.1 pts
Current ratio	1.14×	1.05×	1.02×	0.98×	1.04×	▲ 5.7%
Quick ratio	0.79×	0.72×	0.69×	0.75×	0.80×	▲ 7.3%
Debt to equity	0.14×	0.27×	0.22×	0.33×	0.23×	▼ 31%
Interest coverage	1.93×	-2.36×	0.42×	-0.30×	2.35×	▲ 879%

TEVA price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Drawback: higher risk than most peers: less short-term liquidity (current ratio 0.88 vs a peer median of 2.59) and more debt relative to equity (2.18× vs a peer median of 0.22×)higher risk: less liquidity (current ratio 0.88 vs peers 2.59) and more debt vs equity (2.18× vs peers 0.22×)

About average: valuation

Ranks #523 of 1,157 healthcare companies (top 46%)

See how it ranks against its peers

Worth knowing

Earnings turned from a loss to a profit. Profit per share this year after a loss last year.

Teva Pharmaceutical Industries made a profit per share in its latest year after a loss the year before.

Operating margin at a 6-year high. 12% in 2025, the best of the last 6 years.

Teva Pharmaceutical Industries kept 12% of revenue as operating profit in 2025, its highest in the 6 years of filings we have.

Profit is backed by cash. Free cash flow is 191% of reported profit.

Teva Pharmaceutical Industries's free cash flow is 191% of its reported profit, so its earnings are turning into cash it can reinvest, pay out or use to reduce debt.

Questions investors ask about Teva Pharmaceutical Industries

Is Teva Pharmaceutical Industries getting weaker?

Its latest SEC filing (Jul 29, 2026) got weaker in some ways: operating margin fell 3.9 points to 9.3%. Its overall score is unchanged at 54/100 since Oct 28, 2026.

How is Teva Pharmaceutical Industries valued vs its peers?

Priced about in line with its peers. Valuation scores 55/100 against 1,393 healthcare peers. EBITDA yield 6.9% vs a peer median of 4.0% (stronger than 68% of peers).EBITDA yield 6.9% vs peers 4.0% (stronger than 68% of peers).

Is Teva Pharmaceutical Industries growing?

Yes, faster than most of its peers. Growth scores 76/100 against 1,393 healthcare peers.

How profitable is Teva Pharmaceutical Industries?

More profitable than most of its peers. Profitability scores 80/100 against 1,393 healthcare peers. Return on invested capital 30.9% vs a peer median of 4.7% (stronger than 93% of peers).Return on invested capital 30.9% vs peers 4.7% (stronger than 93% of peers).

How risky is Teva Pharmaceutical Industries?

Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 0.88× vs a peer median of 2.59× (weaker than 93% of peers).Current ratio 0.88× vs peers 2.59× (weaker than 93% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

17.3B USD

17.3B USD

−0.2%

Net income (12 months)

1.6B USD

706.0M USD

−54.9%

Operating margin

13.2%

9.3%

−3.9 pts

Free cash flow (12 months)

1.2B USD

1.3B USD

+14.9%

Cash

3.7B USD

3.7B USD

−2.3%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Gross margin

47.8%

46.7%

48.2%

48.7%

51.8%

▲ 3.0 pts

Operating margin

10.8%

-14.7%

2.7%

-1.8%

12.5%

▲ 14 pts

Net margin

2.6%

-16.4%

-3.5%

-9.9%

8.2%

▲ 18 pts

Return on assets (ROA)

0.9%

-5.6%

-1.3%

-4.2%

3.5%

▲ 7.6 pts

Return on equity (ROE)

4.1%

-31.3%

-7.4%

-30.5%

17.8%

▲ 48 pts

Free cash flow margin

1.5%

7.0%

5.3%

4.5%

6.7%

▲ 2.1 pts

Current ratio

1.14×

1.05×

1.02×

0.98×

1.04×

▲ 5.7%

Quick ratio

0.79×

0.72×

0.69×

0.75×

0.80×

▲ 7.3%

Debt to equity

0.14×

0.27×

0.22×

0.33×

0.23×

▼ 31%

Interest coverage

1.93×

-2.36×

0.42×

-0.30×

2.35×

▲ 879%